https://www.biospace.com/als ALS en-US Thu, 25 Jun 2026 03:29:53 GMT https://www.biospace.com/press-releases/al-s-pharma-presents-ap-101-phase-2-data-supporting-misfolded-sod1-as-a-therapeutic-target-in-als-at-encals-2026 Thu, 25 Jun 2026 03:29:53 GMT https://www.biospace.com/press-releases/al-s-pharma-presents-ap-101-phase-2-data-supporting-misfolded-sod1-as-a-therapeutic-target-in-als-at-encals-2026 https://www.biospace.com/press-releases/leal-therapeutics-doses-first-patient-in-neurals-phase-1-2-trial-of-ltx-002-for-amyotrophic-lateral-sclerosis-als Wed, 24 Jun 2026 03:37:01 GMT https://www.biospace.com/press-releases/leal-therapeutics-doses-first-patient-in-neurals-phase-1-2-trial-of-ltx-002-for-amyotrophic-lateral-sclerosis-als https://www.biospace.com/press-releases/amylyx-pharmaceuticals-to-present-data-from-first-in-human-dose-ranging-phase-1-lumina-trial-of-amx0114-in-als-at-encals-2026 Wed, 24 Jun 2026 02:20:37 GMT https://www.biospace.com/press-releases/amylyx-pharmaceuticals-to-present-data-from-first-in-human-dose-ranging-phase-1-lumina-trial-of-amx0114-in-als-at-encals-2026 https://www.biospace.com/press-releases/trace-neuroscience-initiates-global-clinical-development-program-for-trcn-1023-an-antisense-oligonucleotide-designed-to-restore-unc13a-function-for-the-treatment-of-als Tue, 23 Jun 2026 04:00:17 GMT https://www.biospace.com/press-releases/trace-neuroscience-initiates-global-clinical-development-program-for-trcn-1023-an-antisense-oligonucleotide-designed-to-restore-unc13a-function-for-the-treatment-of-als https://www.biospace.com/press-releases/ab-science-is-invited-to-present-at-the-2026-encals-annual-meeting-the-survival-data-from-masitinib-clinical-program-in-als Wed, 10 Jun 2026 04:02:01 GMT https://www.biospace.com/press-releases/ab-science-is-invited-to-present-at-the-2026-encals-annual-meeting-the-survival-data-from-masitinib-clinical-program-in-als https://www.biospace.com/press-releases/coya-therapeutics-announces-the-first-cohort-of-patients-in-the-alstars-trial-have-begun-the-blinded-active-treatment-extension-phase Tue, 09 Jun 2026 03:39:11 GMT https://www.biospace.com/press-releases/coya-therapeutics-announces-the-first-cohort-of-patients-in-the-alstars-trial-have-begun-the-blinded-active-treatment-extension-phase https://www.biospace.com/press-releases/fnih-names-recipients-of-the-2026-charles-a-sanders-md-partnership-award Thu, 04 Jun 2026 13:03:48 GMT https://www.biospace.com/press-releases/fnih-names-recipients-of-the-2026-charles-a-sanders-md-partnership-award https://www.biospace.com/press-releases/leonabio-presents-on-ath-1105-at-5th-annual-als-drug-development-summit Thu, 04 Jun 2026 12:29:19 GMT https://www.biospace.com/press-releases/leonabio-presents-on-ath-1105-at-5th-annual-als-drug-development-summit https://www.biospace.com/press-releases/everythingals-and-vision-2030-invest-in-allen-institute-initiative-to-accelerate-als-research Wed, 03 Jun 2026 06:49:06 GMT https://www.biospace.com/press-releases/everythingals-and-vision-2030-invest-in-allen-institute-initiative-to-accelerate-als-research https://www.biospace.com/press-releases/pasithea-therapeutics-announces-orphan-drug-designation-by-fda-of-pas-004-for-treatment-of-amyotrophic-lateral-sclerosis-als Tue, 02 Jun 2026 12:23:30 GMT https://www.biospace.com/press-releases/pasithea-therapeutics-announces-orphan-drug-designation-by-fda-of-pas-004-for-treatment-of-amyotrophic-lateral-sclerosis-als https://www.biospace.com/press-releases/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit Wed, 27 May 2026 14:43:44 GMT https://www.biospace.com/press-releases/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit https://www.biospace.com/press-releases/ac-immune-presents-new-phase-1-data-indicating-higher-uptake-of-tdp-43-pet-tracer-aci-19626-in-patients-with-als Fri, 22 May 2026 11:55:25 GMT https://www.biospace.com/press-releases/ac-immune-presents-new-phase-1-data-indicating-higher-uptake-of-tdp-43-pet-tracer-aci-19626-in-patients-with-als https://www.biospace.com/press-releases/outsee-selected-for-discovery-award-from-longitude-prize-on-als-to-accelerate-ai-based-target-discovery Tue, 19 May 2026 11:03:15 GMT https://www.biospace.com/press-releases/outsee-selected-for-discovery-award-from-longitude-prize-on-als-to-accelerate-ai-based-target-discovery https://www.biospace.com/press-releases/neurovision-acquires-durin-life-sciences-to-advance-earlier-detection-and-management-of-neurodegenerative-disease Tue, 12 May 2026 13:21:21 GMT https://www.biospace.com/press-releases/neurovision-acquires-durin-life-sciences-to-advance-earlier-detection-and-management-of-neurodegenerative-disease https://www.biospace.com/press-releases/coya-therapeutics-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update Tue, 12 May 2026 12:30:31 GMT https://www.biospace.com/press-releases/coya-therapeutics-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update https://www.biospace.com/press-releases/coya-therapeutics-has-been-granted-u-s-fda-fast-track-designation-for-coya-302-for-the-treatment-of-amyotrophic-lateral-sclerosis-als Tue, 12 May 2026 12:29:24 GMT https://www.biospace.com/press-releases/coya-therapeutics-has-been-granted-u-s-fda-fast-track-designation-for-coya-302-for-the-treatment-of-amyotrophic-lateral-sclerosis-als https://www.biospace.com/press-releases/the-als-association-awards-3-million-to-bring-expert-als-care-to-communities-that-dont-have-it Fri, 08 May 2026 05:08:24 GMT https://www.biospace.com/press-releases/the-als-association-awards-3-million-to-bring-expert-als-care-to-communities-that-dont-have-it https://www.biospace.com/press-releases/clene-to-present-at-upcoming-may-2026-conferences Tue, 05 May 2026 13:42:45 GMT https://www.biospace.com/press-releases/clene-to-present-at-upcoming-may-2026-conferences https://www.biospace.com/press-releases/after-successful-fda-meeting-clene-filing-accelerated-approval-nda-for-als Mon, 04 May 2026 13:20:34 GMT https://www.biospace.com/press-releases/after-successful-fda-meeting-clene-filing-accelerated-approval-nda-for-als https://www.biospace.com/press-releases/corcept-phase-2-study-of-dazucorilant-demonstrates-two-year-overall-survival-benefit-in-patients-with-amyotrophic-lateral-sclerosis Fri, 01 May 2026 05:00:43 GMT https://www.biospace.com/press-releases/corcept-phase-2-study-of-dazucorilant-demonstrates-two-year-overall-survival-benefit-in-patients-with-amyotrophic-lateral-sclerosis